Home › Drugs › Carboplatin (J9045)

Carboplatin (Paraplatin originator + generic) — HCPCS J9045

Multiple generic manufacturers (originator: Bristol-Myers Squibb Paraplatin, discontinued) · 50/150/450/600 mg single-dose vials (10 mg/mL) · IV infusion 15–60 min · Second-generation platinum cytotoxic

Carboplatin is the platinum backbone of ovarian, NSCLC, SCLC, and head-and-neck regimens — paired with paclitaxel, pemetrexed/pembrolizumab, or etoposide in nearly every cycle. Bill under HCPCS J9045 at 1 unit = 50 mg, with dose calculated by the Calvert formula (AUC × [GFR + 25]), not BSA. A standard AUC 6 / GFR 75 dose = 600 mg = 12 units, drawn from one 600 mg vial. CPT 96413 for the 15–60 min infusion (add 96415 only if >1 hr). JZ or JW required per CMS single-dose container policy. Q2 2026 Medicare reimbursement: $2.937/50 mg unit ($35.24 per AUC 6 dose, ASP + 6%). Document AUC target + GFR or expect denial — the leading audit finding on J9045 claims.

✓ASP data:Q2 2026 (live)
✓Payer policies:verified May 2026
✓NCCN guidelines:v2.2026 Ovarian + NSCLC + SCLC
✓FDA label:Paraplatin + generics
✓Page reviewed:

Instant Answer — the 5 things you need to bill J9045

HCPCS
J9045
1 unit = 50 mg
AUC 6 dose (GFR 75)
12 units
600 mg q21d (Calvert)
Modifiers
JZ or JW
CMS SDV rule; both if vial waste
Admin CPT
96413
15–60 min chemo IV (no 96415 most claims)
Medicare ASP+6%
$2.937
per 50 mg unit, Q2 2026 · $0.059/mg
HCPCS descriptor
J9045 — "Injection, carboplatin, 50 mg" Permanent
Dosing method
Calvert AUC formula: Total dose (mg) = target AUC × (GFR + 25). Not mg/m².
Typical AUC targets
AUC 5–6 (ovarian, NSCLC, SCLC monotherapy or with paclitaxel) · AUC 2 weekly (concurrent chemo-RT, H&N) · AUC 4–5 (with etoposide in SCLC)
Common combos
Carbo/paclitaxel (ovarian, NSCLC) · Carbo/pemetrexed/pembrolizumab (non-sq NSCLC, KEYNOTE-189) · Carbo/paclitaxel/pembrolizumab (sq NSCLC, KEYNOTE-407) · Carbo/etoposide (SCLC) · Carbo/gemcitabine (recurrent ovarian)
NDC (Hospira/Pfizer)
00703-4244-11 (50 mg/5 mL) · 00703-4248-11 (150 mg/15 mL) · 00703-4252-11 (450 mg/45 mL) · 00703-4254-11 (600 mg/60 mL) — representative generic
Vial sizes
50 mg / 5 mL · 150 mg / 15 mL · 450 mg / 45 mL · 600 mg / 60 mL single-dose vials (10 mg/mL aqueous solution); lyophilized 50/150/450 mg powder also marketed
Route
IV infusion over 15–60 minutes per FDA label; faster infusion acceptable in many institutional protocols
Premedication
Moderate-to-high emetogenic chemo: 5-HT3 antagonist + dexamethasone ± NK1 RA. Hypersensitivity premed (steroid + antihistamine + H2 blocker) added at cycle 7+ when reaction risk rises
Boxed warning
Severe bone-marrow suppression (dose-related; cumulative anemia may require transfusion) and anaphylactic-like reactions (within minutes of infusion). Current generic labels (Teva, Hospira/Pfizer, Accord, Fresenius Kabi) carry this boxed warning.
Dose-limiting toxicity
Myelosuppression — especially thrombocytopenia. Less neurotoxic and less nephrotoxic than cisplatin; less neurotoxic than oxaliplatin
Patent / generic status
BMS Paraplatin patent expired 2004; brand discontinued. Many generics (Hospira/Pfizer, Teva, Accord, Fresenius Kabi, Sandoz). Per-mg cost among lowest in cytotoxic class.
Calculate patient estimate → Read full reference Download 1-page PDF
CALVERT FORMULA — show the math or expect a denial.
Carboplatin is the only common chemotherapy dosed by AUC instead of BSA. The Calvert formula is:
Dose (mg) = target AUC × (GFR + 25)

The single most common J9045 denial is documentation that shows only the calculated milligram dose without the underlying target AUC and GFR value used. Both must be in the chart and (often) on the PA submission. Cockcroft-Gault is the most common GFR estimator; some institutions cap GFR at 125 mL/min to prevent overdose in patients with abnormally low serum creatinine.
Phase 1 Identify what you're billing Calvert AUC + GFR → mg → J9045 units in 50 mg increments.

Combination regimens that include carboplatin NCCN v2.2026 verified May 2026

Carboplatin is almost always given with a partner agent. The regimen drives cycle length, AUC target, premedications, and combination admin coding.

RegimenComponentsCarbo doseCyclePrimary indication
Carbo/paclitaxel Carboplatin + paclitaxel 175 mg/m² AUC 6 21 days 1L ovarian (± bevacizumab), NSCLC, endometrial
Carbo/paclitaxel + bevacizumab Adds bevacizumab (J9035) 15 mg/kg AUC 5–6 21 days 1L advanced ovarian + maintenance bev
Carbo/pemetrexed/pembrolizumab Carbo + pemetrexed (J9305) + pembrolizumab (J9271) — KEYNOTE-189 AUC 5 21 days × 4, then maintenance 1L non-squamous metastatic NSCLC
Carbo/paclitaxel/pembrolizumab Carbo + paclitaxel + pembrolizumab — KEYNOTE-407 AUC 6 21 days × 4, then maintenance 1L squamous metastatic NSCLC
Carbo/etoposide Carboplatin + etoposide 100 mg/m² D1–3 AUC 5–6 21 days SCLC (historic backbone), poorly-differentiated NETs
Carbo/etoposide + atezolizumab Adds atezolizumab — IMpower133 AUC 5 21 days × 4, then maintenance 1L extensive-stage SCLC
Carbo/etoposide + durvalumab Adds durvalumab (J9173) — CASPIAN AUC 5–6 21 days × 4, then maintenance 1L extensive-stage SCLC alternative
Carbo/gemcitabine Carboplatin + gemcitabine (J9201) AUC 4 21 days Platinum-sensitive recurrent ovarian; cisplatin-ineligible bladder
Carbo/paclitaxel + trastuzumab Adds trastuzumab (J9355) AUC 6 21 days HER2+ metastatic gastric/GEJ adenocarcinoma (alternative to FLOT)
Weekly carbo + RT Carboplatin weekly + concurrent radiation AUC 2 Weekly × 6–7 wk Locally advanced H&N SCC (cisplatin-ineligible)
The two highest-volume use cases: AUC 6 carbo/paclitaxel q21d for 1L ovarian or 1L NSCLC, and AUC 5 carbo/pemetrexed/pembrolizumab (KEYNOTE-189) q21d for non-squamous metastatic NSCLC. Together these account for the majority of J9045 claim volume in the US.
Combination admin coding: carboplatin is typically billed as the initial drug 96413 (chemo IV, up to 1 hour). Subsequent agents in the cycle (paclitaxel, pemetrexed, etoposide) bill 96417 (each additional sequential infusion). Immunotherapy partners (pembrolizumab, atezolizumab, durvalumab) are immune therapy — they bill 96413/96415 as well when given the same day; sequencing and 96417 rules vary by payer. Verify your charge capture includes every sequential infusion code for the full cycle.

Calvert dosing & unit math FDA label verified May 2026

From the FDA prescribing information (Paraplatin originator + generic SPLs) and the original 1989 Calvert paper.

The Calvert formula — the math that drives every J9045 dose

Carboplatin is dosed to a target area under the curve (AUC), not by body surface area. The Calvert formula is:

# Calvert formula (Calvert et al., J Clin Oncol 1989)
Dose (mg) = target AUC × (GFR + 25)

# GFR = estimated glomerular filtration rate, mL/min (Cockcroft-Gault)
# AUC = target area under the concentration-time curve, mg·min/mL
  • GFR is most commonly estimated by Cockcroft-Gault using actual body weight (use adjusted body weight if BMI > 30)
  • Many institutions cap GFR at 125 mL/min to prevent dosing errors when serum creatinine is abnormally low (e.g., in cachectic patients) — FDA reinforced this guidance in 2010
  • Round to nearest 50 mg increment (= whole-unit J9045 billing), or to nearest 25 mg (= 0.5-unit billing where the system accepts decimals)
  • Bill JZ on the administered units; add JW on a separate line if vial waste exists

AUC-to-units quick reference (AUC 6, common ovarian/NSCLC target)

GFR (mL/min)Dose (mg) = 6 × (GFR+25)Vial(s) drawnTotal drug (mg)Waste (mg)JZ unitsJW units
504501 × 450 = 450450090 (use JZ)
605101 × 450 + 1 × 150 = 60060090~10~2
705701 × 600 = 60060030~11~1
756001 × 600 = 6006000120 (use JZ)
906901 × 600 + 1 × 150 = 75075060~14~1
1007501 × 600 + 1 × 150 = 7507500150 (use JZ)
125 (capped)9001 × 600 + 2 × 150 = 9009000180 (use JZ)

Vial selection: 50 / 150 / 450 / 600 mg sizes. Rounded calculated doses fit 50 mg vial increments cleanly for most GFRs — carboplatin has less partial-vial waste than oxaliplatin (which is BSA-dosed against 50/100/200 mg vials).

Worked example — AUC 5 carbo/pemetrexed/pembrolizumab cycle (KEYNOTE-189)

# Patient: 70 yo female, NSCLC non-sq, SCr 1.0 mg/dL, age 70, weight 65 kg

# Step 1 — estimate GFR via Cockcroft-Gault
GFR = [(140 − 70) × 65] / (72 × 1.0) × 0.85 (female) = 53.7 mL/min

# Step 2 — apply Calvert (AUC 5 target)
Dose = 5 × (53.7 + 25) = 5 × 78.7 = 393.5 mg
Rounded to nearest 50 mg: 400 mg

# Step 3 — vial selection
1 × 450 mg vial drawn = 450 mg total
Administered: 400 mg · Waste: 50 mg

# Step 4 — convert mg to J9045 units (50 mg = 1 unit)
Administered units (JZ line): 400 / 50 = 8 units
Waste units (JW line): 50 / 50 = 1 unit

# Step 5 — admin coding (carbo <= 1 hr infusion)
Carboplatin (initial): 96413 × 1
Pemetrexed (sequential): 96417 × 1
Pembrolizumab (sequential): 96417 × 1

# Drug reimbursement (Q2 2026 ASP+6%)
Drug paid (admin + waste): 9 units × ~$2.937 = ~$26.43
# Note: pembrolizumab on the same line generates many multiples of the carbo cost.

Whole-unit vs decimal-unit billing

J9045 ideally bills in whole units (1 unit = 50 mg). Doses that don't fall on a 50 mg increment (e.g., 475 mg = 9.5 units) are typically rounded to the nearest 50 mg dose at the pharmacy step, so the billing question rarely arises. If your billing system accepts decimal units, 0.5-unit precision is the norm. Confirm with your MAC if the dispensing pharmacy delivers doses not aligned to 50 mg increments.

NDC reference (representative generics) FDA NDC Directory verified May 2026

Multiple manufacturers; submit the actual NDC of the vial used at infusion time. These are common examples seen in oncology buy-and-bill inventory.

ManufacturerNDC (10/11-digit)Vial sizeNotes
Hospira / Pfizer 0703-4244-11 / 00703-4244-11 50 mg / 5 mL 10 mg/mL aqueous SDV; representative generic
Hospira / Pfizer 0703-4248-11 / 00703-4248-11 150 mg / 15 mL Most commonly drawn for AUC 5–6 fill-up
Hospira / Pfizer 0703-4252-11 / 00703-4252-11 450 mg / 45 mL Workhorse vial for adult AUC 5–6 dosing
Hospira / Pfizer 0703-4254-11 / 00703-4254-11 600 mg / 60 mL Exact match for AUC 6 / GFR 75 dose (= 600 mg)
Accord Healthcare 16729-024-63 / 16729-0024-63 450 mg / 45 mL Generic alternative
Fresenius Kabi 63323-710-50 / 63323-0710-50 50 mg / 5 mL Generic alternative
Teva 0703-4244-01 (legacy line) / Teva-branded lots vary 50 mg / 5 mL Teva-marketed generic; lot-specific NDC
Bristol-Myers Squibb (originator Paraplatin) Originator NDCs discontinued n/a BMS withdrew brand Paraplatin after generic entry; bill any generic NDC under J9045
Use the actual NDC of the vial drawn. Multiple generic manufacturers stock similar vial strengths but each NDC is distinct. If your buy-and-bill inventory rotates between Hospira, Accord, and Fresenius Kabi, your billing system should pull the NDC from the lot used at admin time. NDC mismatch between the chart and the claim is a common documentation deficiency in payer audits.
Phase 2 Code the claim 96413 alone covers most encounters (15–60 min). JZ or JW required per CMS SDV rule.

Administration codes CPT verified May 2026

Carboplatin is true cytotoxic chemotherapy — chemo admin codes are required. Most claims do not need 96415 because infusion is 15–60 min.

CodeDescriptionWhen to use
96413 Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug Standard for carboplatin (always primary). One unit per encounter as initial drug. Covers the typical 15–60 min infusion.
96415 Chemotherapy administration, IV infusion; each additional hour Most carbo claims do NOT need this. Add only if documented infusion time exceeds 60 minutes (rare for carboplatin monotherapy).
96417 Chemotherapy administration, IV infusion technique; each additional sequential infusion (different substance/drug) For each subsequent chemo agent in a multi-drug regimen: paclitaxel, pemetrexed, etoposide. One unit per additional agent.
96409 Chemotherapy administration; IV push, single or initial substance/drug NOT used for carboplatin (carbo is infusion, not push).
96365 / 96366 Therapeutic IV infusion (non-chemo) NOT appropriate. Carboplatin is true cytotoxic chemo — chemo admin codes apply. Common biller error.
Infusion duration nuance. The FDA label specifies 15–60 min infusion. Some institutional protocols use 30 min as the default for carboplatin monotherapy and 60 min when given with paclitaxel. If documented chair time for carboplatin alone exceeds 60 min (rare), 96415 × 1 can be added for the second hour. Auditors compare 96415 use against documented infusion time, so order and chart actual times.
Same-day immunotherapy partner sequencing. In KEYNOTE-189 / KEYNOTE-407 cycles, the infusion order is typically pembrolizumab first (its own 96413/96415), then carboplatin (sequential 96417), then pemetrexed/paclitaxel (sequential 96417). Some payers contest 96417 use across drug classes (chemo vs. immune therapy) — verify per-payer; in practice the CPT rule is sequential infusion of a different substance, which is satisfied regardless of class.

Modifiers — JZ or JW required CMS verified May 2026

Why JZ-or-JW for carboplatin (vs JZ+JW for BSA-dosed drugs)

Carboplatin's 50 / 150 / 450 / 600 mg vial range often allows a near-exact match to AUC-calculated doses rounded to 50 mg. Example: AUC 6 / GFR 75 = exactly 600 mg = one 600 mg vial with zero waste → JZ only. When the calculated dose falls between vial sizes — e.g., 400 mg drawn from one 450 mg vial with 50 mg discarded — bill the administered amount with JZ and the discarded amount with JW on a separate line. One of JZ or JW must be on every J9045 claim per CMS's July 2023 single-dose container policy.

ModifierUseExample
JZ Reports zero discarded drug from a single-dose container. Use on the J9045 line for administered units when no waste exists or on the administered line when JW is also billed. AUC 6 / GFR 75 dose: 12 units of J9045 with JZ (600 mg administered, one 600 mg vial, zero waste)
JW Reports the discarded portion of a single-dose vial when waste exists. Use on a separate claim line for the wasted units. AUC 5 / 400 mg dose from 450 mg vial: J9045 with JZ × 8 units (400 mg) + J9045 with JW × 1 unit (50 mg discarded)
25 (E/M) Significant separately identifiable E/M same day as infusion Use on the E/M line, not on J9045. Routine pre-infusion clinical assessment is bundled.
JG / TB 340B-acquired drug modifiers per MAC policy Required if facility participates in 340B and carboplatin is 340B-purchased. Verify per MAC.

Worked JW example — AUC 5, GFR 53.7, dose 400 mg

# Calvert: 5 × (53.7 + 25) = 393.5 mg, rounded to 400 mg
Vial drawn: 1 × 450 mg vial
Administered: 400 mg · Waste: 50 mg

# Claim line 1 (administered)
J9045 × 8 units, modifier JZ (400 mg / 50 mg)

# Claim line 2 (waste, same DOS)
J9045 × 1 unit, modifier JW (50 mg / 50 mg)

# Total billed: 9 units = full 450 mg vial drawn
# Reconcile: JZ + JW units = vial mg drawn / 50
Common audit pattern: claims for AUC-calculated doses that don't round to a 50 mg increment but show JZ-only with no JW (implies whole-vial waste was discarded but not reported). Auditors expect either (a) exact vial match with JZ-only, or (b) JZ + JW lines that reconcile to vials drawn / 50. Reconcile your charge capture for every cycle.
JW reimbursement on carboplatin is modest in absolute dollars (~$2.94 per 50 mg unit wasted, Q2 2026) but at scale (a 1L ovarian carbo/paclitaxel program with 200 patients × 6 cycles) missed JW lines compound to meaningful underpayment. More importantly, missing JW is a CMS compliance flag, not just a money question.

ICD-10-CM by indication FY2026 verified May 2026

Carboplatin is on-label for ovarian cancer and broadly NCCN-supported across NSCLC, SCLC, head-and-neck, endometrial, bladder, and germ-cell malignancies. Use the most specific code supported by encounter documentation.

IndicationICD-10 familyNotes
Ovarian cancer (epithelial)C56.1 / C56.2 / C56.9By laterality. Most common single use of carboplatin in the US. 1L (carbo/paclitaxel ± bev), platinum-sensitive recurrence (carbo/gem, carbo/peg-doxo).
Fallopian tube cancerC57.00–C57.02Treated identically to ovarian per NCCN; same regimens
Primary peritoneal cancerC48.1Treated identically to ovarian per NCCN
NSCLC, non-squamousC34.x + histology Z-code or M-codeCarbo/pemetrexed/pembrolizumab (KEYNOTE-189) 1L metastatic; carbo/paclitaxel adjuvant
NSCLC, squamousC34.x + squamous-cell histologyCarbo/paclitaxel/pembrolizumab (KEYNOTE-407) 1L metastatic
SCLC (small cell lung)C34.x with M-cell specifiedCarbo/etoposide ± atezolizumab (IMpower133) or durvalumab (CASPIAN) for extensive stage
Head & neck SCCC00.x–C14.x, C32.xWeekly AUC 2 carboplatin + concurrent RT in cisplatin-ineligible patients
Endometrial cancerC54.x / C55Carbo/paclitaxel q21d post-surgery; combination with pembrolizumab in advanced/recurrent dMMR (RUBY, KEYNOTE-868)
Bladder / urothelial carcinomaC67.xCarbo/gemcitabine in cisplatin-ineligible patients (split-dose cisplatin preferred when tolerated)
Cervical cancerC53.xCarbo/paclitaxel ± bevacizumab in metastatic / recurrent; cisplatin preferred for concurrent chemo-RT when tolerated
Testicular germ-cell tumorsC62.xSingle-agent AUC 7 carboplatin for stage I seminoma adjuvant; BEP/EP with cisplatin preferred for higher-stage disease
Triple-negative breast cancer (neoadjuvant)C50.x + ER/PR/HER2- documentationCarbo + dose-dense AC-T in some NCCN pathways for TNBC neoadjuvant
Drug-induced thrombocytopeniaD69.59For documenting the dose-limiting toxicity
Anaphylactic reactionT80.52XAHypersensitivity reactions to carboplatin become common after cycle 6–7; document for desensitization protocols
NCCN-compendium documentation matters. Many carboplatin uses (e.g., TNBC neoadjuvant, SCC head-and-neck, endometrial maintenance) are off-label vs the FDA's narrower ovarian-cancer-only carboplatin label but are NCCN-recommended. Submit the relevant NCCN pathway citation in the PA packet for non-ovarian indications, particularly with commercial payers using strict on-label adjudication.

Site of care & place of service Verified May 2026

Carboplatin is administered in physician oncology offices, hospital outpatient infusion centers, ambulatory infusion suites, and oncology ASCs. Because carboplatin is highly to moderately emetogenic (per NCCN antiemesis guideline) and carries a meaningful hypersensitivity-reaction risk that escalates after cycle 6–7, home infusion is uncommon and typically not preferred. Commercial UM aggressively steers infusions out of HOPD after the first 1–3 months for many regimens.

SettingPOSClaim formPayer steering
Physician oncology office11CMS-1500 / 837PPreferred by commercial UM
Ambulatory infusion suite (AIC)49CMS-1500 / 837PPreferred by commercial UM
Oncology ASC24CMS-1500 / 837PAcceptable
Hospital outpatient (on-campus)22UB-04 / 837IDisfavored after first 1–3 months by major commercial plans
Hospital outpatient (off-campus PBD)19UB-04 / 837IDisfavored after first 1–3 months by major commercial plans
Patient home12n/a (rarely done)Not preferred: highly emetogenic; hypersensitivity-reaction risk at cycle 7+
Hypersensitivity-reaction risk drives site-of-care policy. Even commercial UM that aggressively steers biologics out of HOPD accepts in-office or AIC carboplatin administration because of the cumulative hypersensitivity risk that requires resuscitation capacity. Patients with prior reactions are often moved to specialty infusion sites with desensitization protocols. Home carboplatin is not standard of care.

Claim form field mapping Verified May 2026

CMS-1500 / 837P fields for a carboplatin AUC 5 / 400 mg cycle in KEYNOTE-189.

InformationCMS-1500 boxNotes
NPI17bRendering oncologist
NDC qualifier + 11-digit NDC + UoM + qty24A shaded areaN4 + actual lot NDC + ML + total volume drawn (e.g., 45 mL for one 450 mg vial)
HCPCS J9045 + JZ (administered units)24D (drug line 1)Units = administered mg / 50 (e.g., 8 for 400 mg)
HCPCS J9045 + JW (waste units)24D (drug line 2 — separate line)Units = discarded mg / 50 (e.g., 1 for 50 mg)
Drug units (administered)24G line 1e.g., 8 for 400 mg administered
Drug units (waste)24G line 2e.g., 1 for 50 mg discarded
CPT 96413 (admin, initial)24D admin line AOne unit, carboplatin as initial drug
CPT 96417 (each addl sequential)24D admin lines B+One per subsequent agent (pemetrexed, pembrolizumab)
ICD-1021Indication-specific (see ICD-10 table)
PA number23Most commercial payers; required for combo immunotherapy (pembrolizumab) even when carboplatin itself is open-coverage
Calvert AUC + GFR documentationChart / PA packetNot a claim box, but must be in the underlying medical record. Leading audit finding when missing.
Phase 3 Get paid Generic carboplatin rarely the PA bottleneck. The combo agents (pembrolizumab, bevacizumab) are.

Payer policy snapshot Reviewed May 2026

PayerPA (carbo alone)?Concurrent PA on combo agents?Notes
Medicare (MAC LCDs) No (covered for FDA + NCCN-recommended uses) n/a NCD/LCD framework covers carboplatin per FDA label + NCCN compendium for off-label uses (NSCLC, SCLC, H&N, endometrial, etc.)
UnitedHealthcare Yes (oncology medical drug policy) Yes — PA on pembrolizumab, bevacizumab, atezolizumab, durvalumab combos Aggressive site-of-care UM via Optum-managed program for HOPD; carboplatin itself rarely denied on-label
Aetna Yes (CPB + Medical Drug policy) Yes Site-of-care steering after first 1–3 months; AUC + GFR documentation required in PA submission
Cigna / Evernorth Plan-specific; Evicore-managed for many plans Yes Evicore pathway adjudication; NCCN-aligned
BCBS plans Generally no for carboplatin alone; varies by plan Yes for combo biologics / immunotherapy Generally aligned with NCCN guidelines + FDA label

Step therapy

Generally NOT required for carboplatin in FDA-labeled and NCCN-supported indications. In bladder cancer, payers may require documentation of cisplatin-ineligibility (CrCl < 60, hearing loss, neuropathy, ECOG > 1, NYHA class > II heart failure) before approving carboplatin/gemcitabine in lieu of cisplatin-based regimens. Verify per-payer.

The PA fight is rarely about carboplatin itself. Generic carboplatin is cheap and broadly on-pathway. The PA friction comes from the combination agents — pembrolizumab (PD-L1 testing required for some NSCLC pathways), bevacizumab (clinical justification in ovarian), atezolizumab/durvalumab in SCLC, and trastuzumab (HER2 testing required in gastric). Sequence biomarker testing FIRST for any patient who may go on carbo + checkpoint inhibitor or carbo + targeted antibody.

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Q2 2026 payment snapshot — J9045

Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions

ASP + 6%
$2.937
per 50 mg unit
AUC 6 / GFR 75 dose
$35.24
600 mg = 12 units × ASP+6%
AUC 5 / 400 mg dose
$23.50
8 units (admin only) × ASP+6%
Annualized 6-cycle adjuvant carbo/paclitaxel ovarian cost: 6 cycles × ~$35.24/cycle (AUC 6 / GFR 75) = ~$211/year in carboplatin acquisition cost. Among the lowest annualized cytotoxic drug costs because carboplatin has been generic since 2004. The administration code (96413) plus the combination partners (paclitaxel, pembrolizumab, bevacizumab) generate the substantial revenue and OOP burden on a cycle.

Coverage

No NCD specific to carboplatin. Coverage falls under MAC LCDs for chemotherapy plus the generic drug-coverage framework. All MACs cover J9045 for FDA-approved ovarian cancer and for NCCN-compendium- supported off-label uses (NSCLC, SCLC, H&N, endometrial, bladder, etc.) with appropriate ICD-10 documentation. AUC target and GFR value should be in the chart and on PA submissions for commercial payers.

Code history

  • J9045 — "Injection, carboplatin, 50 mg" (permanent)
  • 50 mg unit basis is large relative to other platinum chemo — oxaliplatin J9263 bills per 0.5 mg, cisplatin J9060 per 1 mg. Carboplatin's larger unit aligns with its larger absolute doses (typically 400–900 mg per cycle).

Platinum class comparison

DrugHCPCSUnit basisGenerationPrimary indicationsHallmark toxicity
Carboplatin J9045 50 mg 2nd gen Ovarian, NSCLC, SCLC, H&N, endometrial Myelosuppression (esp. thrombocytopenia); less neurotoxic than cisplatin
Cisplatin J9060 1 mg 1st gen Testicular, bladder, lung, head & neck Nephrotoxicity (requires hydration), ototoxicity, severe nausea, neuropathy
Oxaliplatin J9263 0.5 mg 3rd gen Colorectal, gastric, pancreatic (FOLFOX, FOLFIRINOX, FLOT) Peripheral neuropathy (acute cold-triggered + chronic cumulative); anaphylaxis (boxed)
Class context: Carboplatin replaced cisplatin in many regimens (notably 1L ovarian and most lung) because its better tolerability allows full-dose delivery in outpatient settings without aggressive hydration or admit-for-hydration logistics. Cisplatin retains primacy where its higher absolute efficacy matters (testicular germ-cell, bladder, head-and-neck concurrent chemo-RT in fit patients). Oxaliplatin is the GI-specific platinum. The three are not interchangeable.

Patient assistance Verified May 2026

Generic carboplatin does not have a single manufacturer-sponsored patient assistance program (PAP) the way a branded biologic does. Brand Paraplatin was discontinued by BMS after generic entry and the legacy BMS program ended; current support is delivered through the major oncology foundations and generic manufacturer hardship programs.

  • CancerCare Co-Payment Assistance Foundation — cancercarecopay.org · 1-866-552-6729. Diagnosis-specific funds open and close throughout the year (ovarian, lung, head-and-neck commonly listed). FPL threshold typically 500% (verify at enrollment).
  • PAN Foundation — panfoundation.org · 1-866-316-7263. Disease-specific funds for ovarian, NSCLC, SCLC, and others when open. Annual grant amount varies by fund.
  • HealthWell Foundation — healthwellfoundation.org · 1-800-675-8416. Cancer treatment funds; eligibility typically up to 500% FPL.
  • Patient Advocate Foundation (PAF) Co-Pay Relief — copays.org · 1-866-512-3861. Cancer-specific co-pay support across diagnoses.
  • NeedyMeds — needymeds.org. Aggregator of generic chemo assistance programs across Hospira/Pfizer, Sandoz, Accord, Teva. Verify with your dispensing pharmacy at buy-and-bill time.
  • Local cancer foundations — many disease-specific groups (Ovarian Cancer Research Alliance, Lung Cancer Foundation of America, American Lung Association) maintain emergency funds and travel grants.
Generic carboplatin is rarely the OOP burden. Patient cost concerns on carbo-containing regimens typically come from the combination biologics (pembrolizumab, bevacizumab, atezolizumab, durvalumab) and the infusion administration coinsurance (Medicare Part B 20%). Run a CareCost Estimate to see total cycle OOP including all drugs, admin, premedications, and supportive care — J9045 pre-loaded.
Phase 4 Common denials & FAQ AUC + GFR documentation is the #1 fix. Wrong CPT is #2.

Common denials & how to fix them

Denial reasonCommon causeFix
AUC documentation missingChart shows mg dose but no target AUCAdd the Calvert calculation explicitly: "AUC 6 × (GFR 75 + 25) = 600 mg." Re-submit PA with calc shown. This is the #1 J9045 denial.
GFR not documentedSerum creatinine present but no GFR estimator (Cockcroft-Gault or 24-hr CrCl) shownAdd the Cockcroft-Gault calculation. Note any GFR cap (typically 125 mL/min) per institutional policy. Document weight basis (actual vs. adjusted for BMI > 30).
Wrong admin code (96365)Therapeutic IV billed instead of chemo IVResubmit with 96413. Carboplatin is true cytotoxic chemo — chemo admin codes apply.
96415 billed without >1 hr documentationReflex add of 96415 from an oncology charge templateDrop 96415 unless documented infusion time exceeded 60 min. Standard carbo infusion is 15–60 min.
Missing JZ or JWSingle-dose container claim without JZ/JW modifierAdd JZ on administered line; add JW on separate waste line if vial waste exists. Required since July 2023 CMS policy.
JZ-only on dose that doesn't match a vial sizeCalculated dose doesn't reconcile to vials drawnDocument vial size drawn and add JW waste line if residual was discarded. Auditors flag implausible JZ-only claims with mismatched dose.
NDC mismatch on lotBilled Hospira NDC but Accord or Fresenius Kabi lot dispensedPull NDC from actual lot at admin time. Generic interchange happens at the buy-and-bill level.
Sequential infusion code missing on combo cycleKEYNOTE-189 cycle billed with only 96413 (no 96417 for pemetrexed + pembrolizumab)Add 96417 × 1 unit per subsequent sequential agent. Verify charge capture for full cycle.
Combo biologic PA missingCarbo approved but pembrolizumab/bevacizumab/atezolizumab notSubmit separate PA for each combo agent. PD-L1 (pembro NSCLC pathway), HER2 (trastuzumab gastric), and clinical justification (bevacizumab ovarian) drive approval.
Site-of-care steerage to non-HOPDCommercial UM redirects from HOPD to office/AIC after first 1–3 monthsIf clinically appropriate, transition to in-office or AIC site of service. If clinically necessary in HOPD (high reaction risk, prior anaphylaxis), submit clinical justification.
Step therapy denial in bladder cancerPayer requires documentation of cisplatin-ineligibility before carboDocument CrCl, hearing, neuropathy, ECOG, cardiac status per Galsky cisplatin-ineligibility criteria. Most payers accept Galsky-aligned documentation.

Frequently asked questions

What is the HCPCS code for carboplatin?

Carboplatin (originator Paraplatin, now multi-source generic) is billed under HCPCS J9045 — "Injection, carboplatin, 50 mg." 1 unit = 50 mg. A typical AUC 6 dose for a patient with GFR 75 mL/min = 6 × (75 + 25) = 600 mg = 12 units of J9045. Whole-unit billing aligned to 50 mg vial increments is the norm.

How is carboplatin dose calculated — AUC or mg/m²?

Carboplatin is dosed by AUC using the Calvert formula, NOT by BSA. The formula is: Total dose (mg) = target AUC × (GFR + 25). Typical AUC targets: AUC 5–6 (ovarian/NSCLC monotherapy or with paclitaxel), AUC 2 weekly (concurrent chemo-RT in H&N), AUC 4–5 (with etoposide in SCLC). GFR is most commonly estimated by Cockcroft-Gault using actual body weight; many institutions cap GFR at 125 mL/min to prevent overdose.

Difference between carboplatin and cisplatin billing?

Two different HCPCS codes with different unit bases. Carboplatin bills under J9045 at 1 unit = 50 mg, dosed by AUC (Calvert). Cisplatin bills under J9060 at 1 unit = 1 mg, dosed by mg/m² (BSA). Cisplatin also requires aggressive pre- and post-infusion hydration (separately billable nursing time / E/M); carboplatin generally does not. Cisplatin is preferred when higher efficacy is needed (testicular, bladder, head-and-neck concurrent chemo-RT in fit patients); carboplatin is preferred for better tolerability (ovarian, lung, H&N when cisplatin not tolerated).

Which NDC for which manufacturer?

Most common generic carboplatin in US oncology buy-and-bill: Hospira/Pfizer (0703-4244-11 50 mg, 0703-4248-11 150 mg, 0703-4252-11 450 mg, 0703-4254-11 600 mg). Accord Healthcare (16729-024-63 450 mg), Fresenius Kabi (63323-710-50 50 mg), Teva, and Sandoz also stocked. The originator brand Paraplatin (BMS) is discontinued. Pull the actual NDC from the vial lot at infusion time; submit that NDC on the claim.

Is carboplatin billed with the chemo CPT (96413)?

Yes. CPT 96413 (chemotherapy administration, IV infusion, up to 1 hour) is the standard primary admin code. Standard carboplatin infusion is 15–60 min, so 96413 alone covers most claims. Add 96415 only if documented infusion exceeds 1 hour. For combination regimens, subsequent agents (paclitaxel, pemetrexed, pembrolizumab) bill 96417 (each additional sequential infusion). Do not bill 96365 — that's therapeutic non-chemo IV.

What are the common carboplatin combination regimens?

High-volume: carbo/paclitaxel AUC 6 + paclitaxel 175 mg/m² q21d (1L ovarian ± bevacizumab, NSCLC, endometrial). Carbo/pemetrexed/pembrolizumab AUC 5 q21d (KEYNOTE-189, 1L non-squamous metastatic NSCLC). Carbo/paclitaxel/pembrolizumab AUC 6 q21d (KEYNOTE-407, 1L squamous metastatic NSCLC). Carbo/etoposide ± atezolizumab or durvalumab (extensive-stage SCLC). Carbo/gemcitabine AUC 4 q21d (platinum-sensitive recurrent ovarian; cisplatin-ineligible bladder). Each combination agent has its own HCPCS and admin sequential-infusion billing.

Why is carboplatin's Medicare reimbursement so low?

Carboplatin lost patent protection in 2004 when Bristol-Myers Squibb's brand Paraplatin became generic. Within months, multiple manufacturers (Hospira, Teva, Accord, Fresenius Kabi, Sandoz, others) entered, driving ASP to commodity levels. Per-mg cost is among the lowest of any oncology IV agent. Practice economics on a carboplatin cycle live in chair throughput, administration codes (96413 + 96417), and the combination biologics — not in margin on carboplatin itself.

Is there a manufacturer patient assistance program for carboplatin?

Not in the way a branded biologic has one. The BMS Paraplatin support program ended after brand discontinuation. For patient cost support, use oncology foundations: CancerCare Co-Payment (1-866-552-6729), PAN Foundation (1-866-316-7263), HealthWell Foundation (1-800-675-8416), Patient Advocate Foundation Co-Pay Relief (1-866-512-3861). Generic manufacturers (Hospira/Pfizer, Sandoz, Accord, Teva) maintain limited hardship programs that the dispensing pharmacy can access at buy-and-bill time.

How is carboplatin different from cisplatin and oxaliplatin?

All three are platinum-based DNA-crosslinking cytotoxics, but not interchangeable. Carboplatin (J9045, 50 mg/unit, 2nd gen) is the platinum for ovarian, NSCLC, SCLC, H&N; myelosuppression (especially thrombocytopenia) is the dose-limiting toxicity. Cisplatin (J9060, 1 mg/unit, 1st gen) retains primacy in testicular, bladder, and concurrent chemo-RT; nephrotoxicity is the hallmark. Oxaliplatin (J9263, 0.5 mg/unit, 3rd gen) is the GI-cancer platinum (FOLFOX, FOLFIRINOX, FLOT); peripheral neuropathy is the hallmark. Substituting one platinum for another is regimen-defining, not cosmetic.

Reference Sources & methodology Every claim on this page is sourced. Methodology and review history below.

Source documents

  1. DailyMed — Carboplatin (Paraplatin originator + multiple generic SPLs)
    FDA-approved label; originator NDA 20-452 (Bristol-Myers Squibb 1989), generics post-2004
  2. FDA Paraplatin label PDF (s005, 2010)
    Calvert AUC dosing guidance; GFR cap recommendation; warnings for myelosuppression, hypersensitivity, nephrotoxicity, neuropathy
  3. Calvert AH et al., J Clin Oncol 1989;7(11):1748-1756
    Original derivation of the Calvert formula (AUC = dose / [GFR + 25]); foundation of all carboplatin dosing
  4. CMS — Medicare Part B Drug ASP Pricing File
    Q2 2026 quarterly file, effective April 1 – June 30, 2026
  5. SEER CanMED — HCPCS J9045 reference
    "Injection, carboplatin, 50 mg" — unit basis confirmation
  6. NCI Drug Dictionary — Carboplatin
    Cytotoxic mechanism (DNA crosslinking), indications, class context
  7. NCCN Clinical Practice Guidelines — Ovarian Cancer (v.2.2026)
    Carbo/paclitaxel ± bevacizumab 1L; carbo/gemcitabine recurrent
  8. NCCN Clinical Practice Guidelines — NSCLC (v.2.2026)
    KEYNOTE-189 (carbo/pemetrexed/pembro), KEYNOTE-407 (carbo/paclitaxel/pembro)
  9. NCCN Clinical Practice Guidelines — SCLC (v.2.2026)
    Carbo/etoposide ± atezolizumab (IMpower133) or durvalumab (CASPIAN) for extensive stage
  10. NCCN Clinical Practice Guidelines — Head and Neck (v.2.2026)
    Weekly AUC 2 carboplatin + concurrent RT in cisplatin-ineligible H&N SCC
  11. CMS — JW and JZ modifier policy (MLN Matters, effective July 2023)
    Single-dose container reporting requirement; one of JZ or JW required on every claim
  12. UnitedHealthcare — Oncology Medication Clinical Coverage Policy
  13. Aetna CPB — Ovarian Cancer Treatment
  14. FDA National Drug Code Directory

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

ElementCadenceHow it's refreshed
Medicare ASP pricingQuarterlyAuto-bound to CareCost ASP layer; updates on CMS file release.
Payer policies (UHC, Aetna, BCBS, Cigna)Semi-annualManual review against published payer policy documents.
NCCN regimens (Ovarian / NSCLC / SCLC / H&N)Semi-annualReviewed against NCCN guideline updates.
HCPCS / CPT / modifier rulesAnnualReviewed against CMS HCPCS quarterly files and AMA CPT releases.
NDC, dosing, FDA labelEvent-drivenTied to FDA label revision date and generic NDC additions/withdrawals.

Reviewer

Pending SME review. This page is staff-authored from primary sources (FDA label, CMS, NCCN guidelines, payer policy documents, original Calvert paper — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify each cited source for high-stakes claims.

Change log

  • — SME audit pass. Added boxed-warning row: current generic carboplatin labels (Teva setid f330f5a2-2cad-402f-bcbb-26245a753276) carry a boxed warning for severe bone-marrow suppression and anaphylactic-like reactions — previously not flagged at the at-a-glance.
  • — Initial publication. ASP data: Q2 2026. NCCN: v.2.2026 Ovarian + NSCLC + SCLC + Head & Neck. FDA label: Paraplatin originator + generic SPLs. Ten combo regimens documented (carbo/paclitaxel, carbo/pem/pembro KEYNOTE-189, carbo/pac/pembro KEYNOTE-407, carbo/etoposide ± atezolizumab/durvalumab, carbo/gemcitabine, weekly AUC 2 + RT). Calvert formula worked examples (AUC 6 / GFR 75 and AUC 5 / GFR 53.7 KEYNOTE-189 cycle). Platinum class comparison vs cisplatin (J9060) and oxaliplatin (J9263).

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Combo regimens are verified against NCCN guideline current version and the underlying randomized trials (KEYNOTE-189, KEYNOTE-407, IMpower133, CASPIAN). We do not paraphrase from billing-software vendor blogs.

Stop calculating carboplatin cycle costs by hand.

Pre-loaded with J9045. Real-time ASP. Calvert AUC math. JZ / JW vial-waste lines. Every payer.

Try a free carboplatin estimate →